Cervical Cancer
📧 Sign up to get email alerts when something new happens for Cervical Cancer.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-03-25EMA Authorised: Zirabev (bevacizumab) — Pfizer Europe MA EEIG
Zirabev (bevacizumab) has been authorised by EMA for multiple cancer indications, including colorectal, breast, non-small cell lung, renal c…
-
EMA approval · 2026-02-06EMA Authorised: Alymsys (bevacizumab) — Mabxience Research SL
The EMA authorised Alymsys, a bevacizumab biosimilar from Mabxience Research SL. It is approved for multiple cancer indications including co…
-
EMA approval · 2026-02-05EMA Authorised: Avzivi (bevacizumab) — FGK Representative Service GmbH
EMA authorised Avzivi (bevacizumab) for multiple indications including colorectal cancer, non-small cell lung cancer, renal cell carcinoma, …
-
EMA approval · 2026-01-28EMA Authorised: Abevmy (bevacizumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Abevmy (bevacizumab) as a biosimilar. It is approved for several cancer indications including colorectal, breast, ovarian, fa…
-
EMA approval · 2026-01-28EMA Authorised: Oyavas (bevacizumab) — STADA Arzneimittel AG
EMA authorised Oyavas, a bevacizumab biosimilar by STADA, for multiple indications including colorectal, breast, ovarian, fallopian tube, pe…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-01-28EMA Authorised: Vegzelma (bevacizumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Vegzelma, a bevacizumab biosimilar from Celltrion Healthcare Hungary Kft., for multiple cancers including colorectal, breast,…
-
EMA approval · 2026-01-28EMA Authorised: Aybintio (bevacizumab) — Samsung Bioepis NL B.V.
The EMA authorised Aybintio, a bevacizumab biosimilar from Samsung Bioepis NL B.V., for multiple cancer indications including colorectal, br…
-
EMA approval · 2026-01-27EMA Authorised: Avastin (bevacizumab) — Roche Registration GmbH
The EMA authorised Avastin (bevacizumab) under Roche Registration GmbH for multiple cancer indications. The listed diseases include non-smal…
-
EMA approval · 2026-01-20EMA Authorised: Hycamtin (topotecan) — Sandoz Pharmaceuticals d.d.
EMA authorised Hycamtin (topotecan) by Sandoz Pharmaceuticals d.d. for the treatment of ovarian cancer, cervical cancer, and small cell lung…
-
EMA approval · 2025-01-20EMA Authorised: Potactasol (topotecan) — Actavis Group PTC ehf
The EMA has authorised Potactasol (topotecan) for cervical cancer and small cell lung cancer, with Actavis Group PTC ehf as the marketing au…
-
EMA approval · 2024-11-26EMA Authorised: Cervarix (human papillomavirus1 type 16 L1 protein;human papillomavirus type 18 L1 protein) — GlaxoSmithKline Biologicals S.A.
The European Medicines Agency authorised Cervarix, an HPV vaccine targeting types 16 and 18, for immunization to prevent papillomavirus infe…
-
FDA approval · 2024-05-10FDA Approved: CISPLATIN — Original Application (Apotex Corp.)
FDA approved the original application for cisplatin from Apotex Corp., enabling the generic version to be marketed in the United States.
-
FDA approval · 2024-04-29FDA Approved: TIVDAK — Supplemental Application (SEAGEN INC.)
The FDA approved Seagen's supplemental application for TIVDAK (tisotumab vedotin), resulting in updated labeling to reflect the approved ind…
-
FDA approval · 2023-07-26FDA Approved: TIVDAK — Supplemental Application (SEAGEN INC.)
The FDA approved a supplemental application for Tivdak (tisotumab vedotin) from Seagen Inc., representing additional regulatory action on th…
-
FDA approval · 2023-06-16FDA Approved: CARBOPLATIN — Supplemental Application (Apotex Corp.)
FDA approved Apotex Corp.'s supplemental application for generic carboplatin. This action permits Apotex to market a generic carboplatin for…
-
FDA approval · 2022-04-13FDA Approved: ALYMSYS — Original Application (Amneal Pharmaceuticals LLC)
FDA approves ALYMSYS as a biosimilar to bevacizumab (bevaczizumab-maly) from Amneal Pharmaceuticals LLC under an original Biologics License …
-
FDA approval · 2021-09-20FDA Approved: TIVDAK — Original Application (SEAGEN INC.)
FDA approves Tivdak (tisotumab vedotin) under an original Biologics License Application from Seagen. It is approved for adult patients with …
-
FDA approval · 2020-08-20FDA Approved: TOPOTECAN HYDROCHLORIDE — Supplemental Application (Accord Healthcare, Inc.)
FDA approved Accord Healthcare's supplemental application for Topotecan Hydrochloride, a generic chemotherapy drug, supporting its labeling …
-
FDA approval · 2020-03-05FDA Approved: CARBOPLATIN — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application for carboplatin filed by Apotex Corp., authorizing changes to an approved generic product.
-
FDA approval · 2019-06-27FDA Approved: ZIRABEV — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves ZIRABEV (bevacizumab-bvzr) from Pfizer as a biosimilar to Avastin under an Original Application. The approval covers multiple b…
-
FDA approval · 2018-07-20FDA Approved: GEMCITABINE — Original Application (Sagent Pharmaceuticals)
FDA approves Sagent Pharmaceuticals' original ANDA for gemcitabine, a generic injectable chemotherapy used to treat several cancers.
-
FDA approval · 2017-09-14FDA Approved: MVASI — Original Application (Amgen, Inc)
The FDA approved MVASI (bevacizumab-awwb) from Amgen as a biosimilar to Avastin, marking the original application granting U.S. approval for…
-
FDA approval · 2017-07-06FDA Approved: TOPOTECAN — Original Application (Accord Healthcare Inc.)
The FDA approved Accord Healthcare Inc.'s original application for a generic Topotecan. This approval makes a generic version of Topotecan a…
-
FDA approval · 2017-03-17FDA Approved: CISPLATIN — Original Application (Sagent Pharmaceuticals)
FDA approved Sagent Pharmaceuticals' original application for cisplatin, a generic injectable chemotherapy agent (ANDA approval).
-
FDA approval · 2017-01-19FDA Approved: CISPLATIN — Supplemental Application (WG Critical Care, LLC)
The FDA approved a supplemental application for cisplatin submitted by WG Critical Care, LLC.